NCT01805258View on ClinicalTrials.gov

Efficacy and Safety of Concomitant Use of Nevirapine and Rifampicin With HIV-TB

PHASE3CompletedINTERVENTIONAL
Enrollment

135

Participants

Timeline

Start Date

June 30, 2007

Primary Completion Date

December 31, 2012

Study Completion Date

February 28, 2013

Conditions
HIV/TB Co-infection
Interventions
DRUG

Nevirapine

The regimen containing Nevirapine: 3TC/ZDV 150/300 mg 1 tablet BID + NEVIRAPINE 200 mg qD for 2 weeks then 200mg BID

DRUG

Efavirenz

The regimen containing Efavirenz: 3TC/ZDV 150/300 mg 1 tablet BID + EFAVIRENZ 600 mg qD

Trial Locations (1)

110029

All India Institute of Medical Sciences, New Delhi

All Listed Sponsors
collaborator

National AIDS Control Organisation

OTHER

lead

All India Institute of Medical Sciences

OTHER

NCT01805258 - Efficacy and Safety of Concomitant Use of Nevirapine and Rifampicin With HIV-TB | Biotech Hunter | Biotech Hunter